Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 23 2022 - 3:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2022 (No. 1)
Commission File Number 001-37846
QUOIN PHARMACEUTICALS
LTD.
(Translation of registrant’s name into English)
Azrieli Center, Round Tower, 30th Floor
132 Menachem Begin Blvd
Tel Aviv, 6701101
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F
x Form 40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
Unaudited Interim Financial Statements as of,
and for the period ended, March 31, 2022, and Related Management’s Discussion and Analysis of Financial Condition and Results
of Operations
On May 23, 2022, Quoin Pharmaceuticals, Inc.
(“Quoin”), a wholly-owned subsidiary of Quoin Pharmaceuticals Ltd. (the “Company”), issued unaudited interim financial
statements as of, and for the period ended, March 31, 2022, together with the related Quoin’s Management Discussion and Analysis
of Financial Condition and Results of Operations, attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated
by reference herein.
The information in this Form 6-K, including
the exhibits hereto, shall be incorporated by reference into the Company’s registration statements on Form S-8 (Registration
Nos. 333-214817, 333-220015, 333-225003 and 333-232230), on Form F-3 (Registration Nos. 333-219614 and 333-229083).
Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: May 23, 2022 |
QUOIN PHARMACEUTICALS LTD. |
|
|
|
By: |
/s/ Gordon Dunn |
|
Name: |
Gordon Dunn |
|
Title: |
Chief Financial Officer |
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Oct 2023 to Oct 2024